Pierre Massion
Faculty Member
Last active: 1/11/2018

  1. Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement. Mazzone PJ, Sears CR, Arenberg DA, Gaga M, Gould MK, Massion PP, Nair VS, Powell CA, Silvestri GA, Vachani A, Wiener RS, ATS Assembly on Thoracic Oncology (2017) Am J Respir Crit Care Med 196(7): e15-e29
    › Primary publication · 28960111 (PubMed) · PMC5803661 (PubMed Central)
  2. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. Gardner EE, Lok BH, Schneeberger VE, Desmeules P, Miles LA, Arnold PK, Ni A, Khodos I, de Stanchina E, Nguyen T, Sage J, Campbell JE, Ribich S, Rekhtman N, Dowlati A, Massion PP, Rudin CM, Poirier JT (2017) Cancer Cell 31(2): 286-299
    › Primary publication · 28196596 (PubMed) · PMC5313262 (PubMed Central)
  3. Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography and Nodule-Based Risk Models for Detection of Lung Cancer. Massion PP, Healey GF, Peek LJ, Fredericks L, Sewell HF, Murray A, Robertson JF (2017) J Thorac Oncol 12(3): 578-584
    › Primary publication · 27615397 (PubMed) · PMC5367043 (PubMed Central)
  4. A 3q gene signature associated with triple negative breast cancer organ specific metastasis and response to neoadjuvant chemotherapy. Qian J, Chen H, Ji X, Eisenberg R, Chakravarthy AB, Mayer IA, Massion PP (2017) Sci Rep : 45828
    › Primary publication · 28387221 (PubMed) · PMC5384279 (PubMed Central)
  5. 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. Walker R, Deppen S, Smith G, Shi C, Lehman J, Clanton J, Moore B, Burns R, Grogan EL, Massion PP (2017) PLoS One 12(2): e0171301
    › Primary publication · 28182730 (PubMed) · PMC5300187 (PubMed Central)
  6. The Pursuit of Noninvasive Diagnosis of Lung Cancer. Atwater T, Cook CM, Massion PP (2016) Semin Respir Crit Care Med 37(5): 670-680
    › Primary publication · 27732989 (PubMed) · PMC5317274 (PubMed Central)
  7. The airway epithelium undergoes metabolic reprogramming in individuals at high risk for lung cancer. Rahman SMJ, Ji X, Zimmerman LJ, Li M, Harris BK, Hoeksema MD, Trenary IA, Zou Y, Qian J, Slebos RJ, Beane J, Spira A, Shyr Y, Eisenberg R, Liebler DC, Young JD, Massion PP (2016) JCI Insight 1(19): e88814
    › Primary publication · 27882349 (PubMed) · PMC5111517 (PubMed Central)
  8. Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes? Bunn PA, Minna JD, Augustyn A, Gazdar AF, Ouadah Y, Krasnow MA, Berns A, Brambilla E, Rekhtman N, Massion PP, Niederst M, Peifer M, Yokota J, Govindan R, Poirier JT, Byers LA, Wynes MW, McFadden DG, MacPherson D, Hann CL, Farago AF, Dive C, Teicher BA, Peacock CD, Johnson JE, Cobb MH, Wendel HG, Spigel D, Sage J, Yang P, Pietanza MC, Krug LM, Heymach J, Ujhazy P, Zhou C, Goto K, Dowlati A, Christensen CL, Park K, Einhorn LH, Edelman MJ, Giaccone G, Gerber DE, Salgia R, Owonikoko T, Malik S, Karachaliou N, Gandara DR, Slotman BJ, Blackhall F, Goss G, Thomas R, Rudin CM, Hirsch FR (2016) J Thorac Oncol 11(4): 453-74
    › Primary publication · 26829312 (PubMed) · PMC4836290 (PubMed Central)
  9. Preclinical Evaluation of 4-[18F]Fluoroglutamine PET to Assess ASCT2 Expression in Lung Cancer. Hassanein M, Hight MR, Buck JR, Tantawy MN, Nickels ML, Hoeksema MD, Harris BK, Boyd K, Massion PP, Manning HC (2016) Mol Imaging Biol 18(1): 18-23
    › Primary publication · 25971659 (PubMed) · PMC4644503 (PubMed Central)
  10. Lung cancer risk test trial: study design, participant baseline characteristics, bronchoscopy safety, and establishment of a biospecimen repository. Crawford EL, Levin A, Safi F, Lu M, Baugh A, Zhang X, Yeo J, Khuder SA, Boulos AM, Nana-Sinkam P, Massion PP, Arenberg DA, Midthun D, Mazzone PJ, Nathan SD, Wainz R, Silvestri G, Tita J, Willey JC (2016) BMC Pulm Med : 16
    › Primary publication · 26801409 (PubMed) · PMC4722707 (PubMed Central)